This study is looking at how well Niyad (nafamostat mesylate) works to prevent blood clots in the dialysis machine (CRRT circuit) for people with acute kidney injury. This is for patients who cannot use heparin or have a high risk of bleeding. You might be able to join if you are between 18 and 80 years old and need continuous renal replacement therapy (CRRT) or started it within the last 48 hours. You cannot join if you weigh less than 50 kg, are already on blood thinners, or have active bleeding. The study will compare Niyad to a placebo (a salt water solution) to see which is better at preventing clots in the dialysis filter after 24 hours. The current recruitment status is unclear.

Study design

This is a prospective, randomized, placebo-controlled study with a planned enrollment of 70 participants. Participants will receive either Niyad or a placebo.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 24 hours, focusing on post-filter activated clotting time.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.